FEATURED ARTICLES
Speeding Research With Data Mining Expertise
According to The STM Report (2015), more than 2.5 million peer-reviewed articles are published in scholarly journals each year. PubMed alone contains more than 25 million citations for biomedical journal articles from MEDLINE. The amount and availability of content for clinical researchers has never been greater – but finding the right articles to use is becoming more difficult.
-
![RDClinicalTrials_May_2013_pic]( "Repurposing And Rescuing Pharmaceutical Drugs")
Repurposing And Rescuing Pharmaceutical DrugsRepurposing marketed drugs or rescuing compounds that failed in clinical trials offers entrepreneurs the potential to replenish pipelines with reduced risk and time.
-
![Ed Miseta]( "The High Cost of Clinical Research – Who’s To Blame And What Can Be Done?")
The High Cost of Clinical Research – Who’s To Blame And What Can Be Done?The cost of new drug discovery has skyrocketed in recent years, and is something that should have everyone in the drug discovery industry concerned. Sergei Varshavsky, M.D., Ph.D., and senior VP of global strategy for contract research firm Synergy Research Group (SynRG), notes it was not always this way. Some of the greatest medicinal discoveries in the history of mankind were inexpensive to develop and test. “There was the discovery of the smallpox vaccine in 1796, ether anesthesia in 1846, and insulin and penicillin in the early 20th century,” he says. “None of them cost much. In fact, the patent for insulin was sold to the University of Toronto for a half-dollar. Despite the low cost, these drugs have saved billions of lives.” Unfortunately today’s medical community is no longer able to accomplish similar feats for such a low cost.
-
![ClinicalTrialsADCMarch2013]( "ADC: The Next Big Opportunity For Oncology Drugs")
ADC: The Next Big Opportunity For Oncology DrugsThe commercial success of mAb products such as Rituxan, Erbitux, and Herceptin has catapulted mAbs to the forefront of molecular medicine.
